SNTI (Senti Biosciences Holdings) Other Current Payables: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SNTI Senti Biosciences Holdings Inc SNTI
23 GF Score
Price $0.48
! 6 Warning Signs
View Full Analysis

What is Senti Biosciences Holdings Other Current Payables?

Senti Biosciences Holdings SNTI -18.18% 23 Other Current Payables is $0.00 Mil as of Mar. 2026. GuruFocus rates SNTI with a GF Score™ of 23/100. The stock has 6 warning signs investors should review.

Senti Biosciences Holdings's Other Current Payables for the quarter that ended in Mar. 2026 was $0.00 Mil.

Senti Biosciences Holdings Other Current Payables Related Terms

Senti Biosciences Holdings Other Current Payables Historical Data

* Premium members only.

The historical data trend for Senti Biosciences Holdings's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Senti Biosciences Holdings Other Current Payables Chart

Senti Biosciences Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Senti Biosciences Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SNTI
23GF Score
Senti Biosciences Holdings Inc SNTI
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Senti Biosciences Holdings Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0.00 Mil mean?
Senti Biosciences Holdings (SNTI) has a Other Current Payables of $0.00 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Senti Biosciences Holdings and its competitors.
Is Senti Biosciences Holdings' Other Current Payables too high?
Senti Biosciences Holdings' current Other Current Payables is $0.00 Mil. Overall, Senti Biosciences Holdings has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Senti Biosciences Holdings' Other Current Payables compare to ALGS and CRVO?
Senti Biosciences Holdings' Other Current Payables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Senti Biosciences Holdings and its competitors. Senti Biosciences Holdings's current Other Current Payables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senti Biosciences Holdings stock overvalued right now?
Senti Biosciences Holdings (SNTI) has a current Other Current Payables of $0.00 Mil. The current Other Current Payables is $0.00 Mil. Senti Biosciences Holdings' overall GF Score™ is 23/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Senti Biosciences Holdings (SNTI), the current Other Current Payables is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Senti Biosciences Holdings Business Description

Address 2 Corporate Drive, First Floor, South San Francisco, CA, USA, 94080
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
23GF Score

Get the complete analysis for SNTI

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.48
Price